Viking Therapeutics' Weight-Loss Tablet Shows 3.3% Reduction in Early Clinical Study
Tuesday, 26 March 2024, 13:23
Viking Therapeutics Weight-Loss Tablet Study Results
Viking Therapeutics conducted an early-stage trial where volunteers experienced weight reduction using the experimental tablet, VK2735. The highest 40-milligram dose showed a notable weight loss of 3.3% compared to the placebo group after 28 days.
Market Trends in Weight-Loss Drugs
- Leading companies like Eli Lilly and Novo Nordisk are exploring oral versions of weight-loss medications to provide patients with more convenient treatment options.
- Viking Therapeutics' positive trial results indicate a potential shift towards effective oral weight-loss solutions in the market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.